Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Update

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 1,452,613 shares, a drop of 51.0% from the June 15th total of 2,962,839 shares. Currently, 4.3% of the shares of the company are short sold. Based on an average daily volume of 1,062,756 shares, the short-interest ratio is presently 1.4 days.

Theriva Biologics Stock Performance

Shares of NYSEAMERICAN TOVX traded up $0.00 during midday trading on Wednesday, reaching $0.24. 560,830 shares of the stock were exchanged, compared to its average volume of 2,665,299. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.63 and a quick ratio of 1.63. The firm has a 50-day simple moving average of $0.28 and a two-hundred day simple moving average of $0.24. Theriva Biologics has a twelve month low of $0.16 and a twelve month high of $0.86.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its earnings results on Tuesday, May 5th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $0.30 million for the quarter.

Wall Street Analyst Weigh In

Separately, Maxim Group raised Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Theriva Biologics presently has a consensus rating of “Buy” and a consensus target price of $1.00.

Institutional Investors Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Two Sigma Investments LP purchased a new stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned approximately 0.64% of Theriva Biologics as of its most recent SEC filing. Institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.